Dihydropyrimidine dehydrogenase (NADP+)

The systematic name of this enzyme class is 5,6-dihydrouracil:NADP+ 5-oxidoreductase.
Other names in common use include:

• dihydrothymine dehydrogenase
• dihydrouracil dehydrogenase (NADP+)
• 4,5-dihydrothymine: oxidoreductase
• DPD
• DHPDH
• dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide, phosphate)
• DHU dehydrogenase
• hydropyrimidine dehydrogenase
• dihydropyrimidine dehydrogenase (NADP+)

As of late 2007, 5 structures have been solved for this class of enzymes, with PDB accession codes 1GT8, 1GTE, 1GTH, 1H7W, and 1H7X.

The protein is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Genetic deficiency of this enzyme results in an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy.^[2]

Click on genes, proteins and metabolites below to link to respective articles.^{[§ 1]}

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|alt=Fluorouracil (5-FU) Activity edit]]

Fluorouracil (5-FU) Activity edit

1. [§ 1]

   The interactive pathway map can be edited at WikiPathways: "FluoropyrimidineActivity_WP1601".

• Dihydropyrimidine dehydrogenase deficiency, a genetic disorder
• Cancer pharmacogenomics